Skip to main content
. 2023 Jan 4;18(1):e0280023. doi: 10.1371/journal.pone.0280023

Fig 4. Ex-vivo and in vivo cytotoxic assay for human CIK cells.

Fig 4

A. Ex-vivo cytotoxicity assay of CIK cells against human cancer cell lines in terms of the percentage of cells expressing Annexin 5 and AAD7. In the case of the K562 cell line, the effector:target ratio (E:T) ranged from 1:10 to 5:1 (N = 3). In the case of the HepG2 cell lines, the E:T ratio ranged from 1:1 to 20:1; (N = 1). In the case of the J7 cell line, we used ATP methods at a fixed E:T ratio at 5:1, the positive control used Triton-X 100 (N = 5). B. The figure on the right illustrates the scheme of human CIK cells adoptive transfer model. Six-week-old NOD/SCID mice were injected with the human J7 cell line. When tumors grew to 0.2 cm, mice were adoptively transferred with human CIK cells every 4 days. The table lists the growth rates of J7 tumors cells on human CIK cells or in PB injected mice (N = 5, *p < 0.05, **p < 0.005). C. The dot figure shows the percentages of human CD45+ cells on tumor infiltrating immune cells on control and CIK cells injected in NOD/SCID mice. The photographs show hematoxylin & eosin staining results from control and human CIK cell-injected mice, as well as the human CD4 and CD8 immunohistochemistry stains on tumor specimens.